Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis

被引:0
作者
Zeydan, Burcu [1 ,2 ]
Azevedo, Christina J. [3 ]
Makhani, Naila [4 ,5 ]
Cohen, Mikael [6 ]
Tutuncu, Melih [7 ]
Thouvenot, Eric [8 ,9 ]
Siva, Aksel [7 ]
Okuda, Darin T. [10 ,11 ]
Kantarci, Orhun H. [2 ]
Lebrun-Frenay, Christine [6 ]
机构
[1] Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA
[3] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[4] Yale Sch Med, Dept Pediat, New Haven, CT USA
[5] Yale Sch Med, Dept Neurol, New Haven, CT USA
[6] Cote Azur Univ, Pasteur 2 Univ Hosp, Dept Neurol, MS Clin Nice,UR2CA URRIS, Nice, France
[7] Istanbul Univ, Cerrahpasa Sch Med, Dept Neurol, Istanbul, Turkiye
[8] Univ Montpellier, Nimes Univ Hosp Ctr, Dept Neurol, Nimes, France
[9] Montpellier Univ, IGF, CNRS, INSERM, Montpellier, France
[10] Univ Texas Southwestern Med Ctr, Neuroinnovat Program, Dallas, TX USA
[11] Univ Texas Southwestern Med Ctr, Multiple Sclerosis & Neuroimmunol Imaging Program, Dallas, TX USA
基金
美国国家卫生研究院;
关键词
RADIOLOGICALLY ISOLATED SYNDROME; INTRAMUSCULAR INTERFERON BETA-1A; 1ST DEMYELINATING EVENT; CLINICALLY DEFINITE; FOLLOW-UP; CONVERSION; ASSOCIATION; DIAGNOSIS; REVISIONS; PHASE;
D O I
10.1007/s40263-024-01117-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Radiologically isolated syndrome (RIS) is the earliest stage in the disease continuum of multiple sclerosis (MS). RIS is discovered incidentally in individuals who are asymptomatic but have typical lesions in the brain and/or spinal cord suggestive of demyelination. The 2009 and revised 2023 RIS criteria were developed for diagnosis. Presymptomatic individuals who fulfill the 2009 RIS criteria by having 3-4 of 4 dissemination in space McDonald 2005 MS criteria are still diagnosed with RIS using the revised 2023 RIS criteria. In presymptomatic individuals who do not fulfill the 2009 RIS criteria, the revised 2023 RIS criteria target to secure an accurate and timely diagnosis: In addition to (a) having one lesion in two of four locations (periventricular, juxtacortical/cortical, infratentorial, spinal cord), (b) two of three features (spinal cord lesion, cerebrospinal fluid (CSF)-restricted oligoclonal bands, and new T2 or gadolinium-enhancing lesion) should be fulfilled. Among laboratory biomarkers, CSF kappa-free light chain can also increase diagnostic accuracy. Once the diagnosis is confirmed, the established risk factors, including demographics, imaging, and laboratory biomarkers, should be evaluated for symptomatic MS transition and prognosis. Younger age, male sex, increased neurofilament-light chain, CSF abnormality, and the presence of infratentorial, spinal cord, or gadolinium-enhancing lesions on imaging are the main risk factors for transition to symptomatic MS. Two randomized clinical trials showed significant efficacy of disease-modifying treatments in delaying or preventing the development of the first clinical event in RIS. However, because some individuals remain as RIS, it is crucial to identify the individuals with a higher number of risk factors to optimize disease outcomes by early intervention while minimizing adverse events. Discussing each RIS case with an expert MS team is recommended because there is still a lack of clinical guidelines to improve care, counseling, and surveillance.
引用
收藏
页码:973 / 983
页数:11
相关论文
共 50 条
  • [31] Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)
    Wiendl, Heinz
    Gold, Ralf
    Berger, Thomas
    Derfuss, Tobias
    Linker, Ralf
    Maeurer, Mathias
    Stangel, Martin
    Aktas, Orhan
    Baum, Karl
    Berghoff, Martin
    Bittner, Stefan
    Chan, Andrew
    Czaplinski, Adam
    Deisenhammer, Florian
    Di Pauli, Franziska
    Du Pasquier, Renaud
    Enzinger, Christian
    Fertl, Elisabeth
    Gass, Achim
    Gehring, Klaus
    Gobbi, Claudio
    Goebels, Norbert
    Guger, Michael
    Haghikia, Aiden
    Hartung, Hans-Peter
    Heidenreich, Fedor
    Hoffmann, Olaf
    Hunter, Zoe R.
    Kallmann, Boris
    Kleinschnitz, Christoph
    Klotz, Luisa
    Leussink, Verena
    Leutmezer, Fritz
    Limmroth, Volker
    Luenemann, Jan D.
    Lutterotti, Andreas
    Meuth, Sven G.
    Meyding-Lamade, Uta
    Platten, Michael
    Rieckmann, Peter
    Schmidt, Stephan
    Tumani, Hayrettin
    Weber, Martin S.
    Weber, Frank
    Zettl, Uwe K.
    Ziemssen, Tjalf
    Zipp, Frauke
    [J]. NERVENARZT, 2021, 92 (08): : 773 - 801
  • [32] Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis
    Li, Pengxiang
    Ladage, Vrushabh P.
    Berger, Joseph
    Chahin, Salim
    Jhaveri, Mehul
    Geremakis, Caroline
    Doshi, Jalpa A.
    [J]. VALUE IN HEALTH, 2020, 23 (03) : 328 - 334
  • [33] Initial high-efficacy disease-modifying therapy in multiple sclerosis A nationwide cohort study
    Buron, Mathias Due
    Chalmer, Thor Ameri
    Sellebjerg, Finn
    Barzinji, Ismael
    Christensen, Jeppe Romme
    Christensen, Mette Kirstine
    Hansen, Victoria
    Illes, Zsolt
    Jensen, Henrik Boye
    Kant, Matthias
    Papp, Viktoria
    Petersen, Thor
    Rasmussen, Peter Vestergaard
    Schafer, Jakob
    Theodorsdottir, Asta
    Weglewski, Arkadiusz
    Sorensen, Per Soelberg
    Magyari, Melinda
    [J]. NEUROLOGY, 2020, 95 (08) : E1041 - E1051
  • [34] The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden
    Kotsopoulos, Nikolaos
    Connolly, Mark P.
    Dort, Thibaut
    Kavaliunas, Andrius
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (08) : 831 - 837
  • [35] Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review
    Reen, Gurpreet K.
    Silber, Eli
    Langdon, Dawn W.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 375 : 107 - 122
  • [36] Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis
    Tedeholm, H.
    Piehl, F.
    Lycke, J.
    Link, J.
    Stawiarz, L.
    Burman, J.
    de Flon, P.
    Fink, K.
    Gunnarsson, M.
    Mellergard, J.
    Nilsson, P.
    Sundstrom, P.
    Svenningsson, A.
    Johansson, H.
    Andersen, O.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [37] Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies
    Wnuk, Marcin
    Drabik, Leszek
    Marona, Monika
    Szaleniec, Joanna
    Bryll, Amira
    Karcz, Paulina
    Kolasinska, Justyna
    Kolasinska, Monika
    Ziekiewicz, Maciej
    Skladzien, Jacek
    Popiela, Tadeusz
    Slowik, Agnieszka
    [J]. ENT-EAR NOSE & THROAT JOURNAL, 2022, 101 (10) : 640 - 644
  • [38] Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
    Neuberger, Edward E.
    Abbass, Ibrahim M.
    Jones, Eddie
    Engmann, Natalie J.
    [J]. NEUROLOGY AND THERAPY, 2021, 10 (01) : 183 - 196
  • [39] Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naive Patients
    Freeman, Leorah
    Kee, Arianna
    Tian, Marc
    Mehta, Rina
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 65 - 75
  • [40] Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis
    Sriwastava, Shitiz
    Kataria, Saurabh
    Srivastava, Samiksha
    Kazemlou, Shaghayegh
    Gao, Si
    Wen, Sijin
    Saber, Hamidreza
    Tripathi, Richa
    Sheikh, Zubeda
    Peterson, Sarah
    Gwinn, Ronald
    Bernitsas, Evanthia
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2021, 360